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Introduction
Recessive mutations in Cat Eye syndrome Critical
Region 1 (CECR1), the gene encoding adenosine deami-
nase 2 (ADA2) have been recently reported to cause
polyarteritis nodosa (PAN) with highly varied clinical
expression.
Objectives
The aim of this study was to identify the relevance of
this mutation in children with PAN at Great Ormond
Street Hospital (GOSH).
Patients and methods
We used next generation (NGS) and Sanger sequencing
to study select paediatric cases of PAN. Inclusion criteria
were: 1. Onset of PAN <age-10-years; 2. Suspected famil-
ial PAN; 3. Sporadic PAN particularly with neurological
involvement; and 4. Clinical features resembling the
recent description of deficiency of ADA2 (DADA2).
Whole exome sequencing was performed using a com-
mercially available kit (Illumina) and a NextSeq500
sequencer. We used the Infinium HumanCytoSNP-12
v2.1 DNA Analysis BeadChip Kit for homozygosity map-
ping. Sanger sequencing was performed using the
Applied Biosystems 3730 DNA Analyzer. ADA2 enzy-
matic assay was performed using Diazyme ADA Test Kit.
Results
Fourteen patients with PAN and one patient with
unclassified vasculitis were included. Mutations in
CECR1 were identified in 8 patients: 4 homozygous
mutations and 4 compound heterozygous mutations. Of
the 8 patients with CECR1 mutation, all had the evi-
dence of systemic inflammation; 8/8 had cutaneous vas-
culitis; 3/8 had arterial ischaemic stroke; 3/8 had
vasculitic polyneuropathy; 1/8 had long-tract signs,
cause undetermined; and 3/8 had B cell immunodefi-
ciency. Four/8 ultimately required treatment with anti-
TNF-alpha having failed other treatments. We also
screened 25 subjects from 7 families related to the index
cases with DADA2. Homozygous (n=4) or compound
heterozygous mutations (n=1) were identified in 5/25 of
these asymptomatic subjects. ADA2 enzyme activity in
both affected and asymptomatic subjects with CECR1
mutations was significantly lower compared to healthy
paediatric controls (p value = 0.0022) and sporadic PAN
patients without CECR1 mutation (p value = 0.0189).
Conclusions
We identified DADA2 as the cause of vasculitis in 8/15
(53%) of cases with childhood PAN; and 5 currently
asymptomatic cases in their relatives. The clinical severity
of DADA2 is heterogeneous ranging from asymptomatic
to full-blown systemic PAN. It is currently unknown how
DADA2 causes vasculitis. Possibilities include alteration of
macrophage biology; endothelial activation; effect of
chronic high extracellular adenosine; and/or other as yet
poorly defined immunodysregulation (with or without
immunodeficiency). Irrespective of the mechanism, TNF
blockade seems to be effective therapeutically. Homozy-
gous symptomatic patients may first present in middle age
hence asymptomatic DADA2 requires close monitoring.
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